Qube Research & Technologies (QRT)
ATOS icon

Qube Research & Technologies (QRT)’s Atossa Therapeutics ATOS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,853
Closed -$43K – 3525
2025
Q4 		$43K Sell
4,853
-4,390
-47% -$55.5K ﹤0.01% 3298
2025
Q3 		$120K Sell
9,243
-18,515
-67% -$229K ﹤0.01% 3030
2025
Q2 		$346K Buy
27,758
+21,689
+357% +$259K ﹤0.01% 2790
2025
Q1 		$61.3K Sell
6,069
-6,570
-52% -$79.8K ﹤0.01% 3086
2024
Q4 		$179K Sell
12,639
-400
-3% -$7.81K ﹤0.01% 2858
2024
Q3 		$297K Buy
13,039
+2,544
+24% +$51.4K ﹤0.01% 2432
2024
Q2 		$187K Sell
10,495
-6,086
-37% -$135K ﹤0.01% 2441
2024
Q1 		$448K Buy
16,581
+16,577
+414,425% +$266K ﹤0.01% 2592
2023
Q4 		$48 Hold
4
– – ﹤0.01% 4072
2023
Q3 		$40 Buy
+4
New +$58 ﹤0.01% 3833
2022
Q4 		– Sell
-6,112
Closed -$76K – 2455
2022
Q3 		$76K Sell
6,112
-933
-13% -$13.5K ﹤0.01% 2048
2022
Q2 		$115K Buy
+7,045
New +$111K ﹤0.01% 1890
2022
Q1 		– Sell
-19,199
Closed -$461K – 2430
2021
Q4 		$461K Buy
+19,199
New +$703K ﹤0.01% 1614

Other funds holding ATOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ATOS Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 4,853 shares — an estimated $43K sold.

Qube Research & Technologies (QRT) first reported a position in ATOS in Q4 2021 and held it in 13 quarters. The position peaked at $461K in Q4 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • Qube Research & Technologies (QRT) reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 4,853 Atossa Therapeutics shares in Q1 2026, an estimated $43K.
  • Qube Research & Technologies (QRT) first reported a position in Atossa Therapeutics in Q4 2021 and held it in 13 quarters.
  • Qube Research & Technologies (QRT)'s Atossa Therapeutics position peaked at $461K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.